GlassScriptPhysician profile
Priya Bhogaita
NPI 1598389397
$1,887.08
in general payments reported to CMS, 2019-2025
20 companies · $596 in 2025
The $596 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $118 · 2022: $265 · 2023: $86.86 · 2024: $821 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,503.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $355.00 | 2024-2025 | Fasenra, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.56 | 2023-2025 | Spiriva, Ofev, Jascayd |
| Takeda Pharmaceuticals U.S.A., INC. | $161.86 | 2024-2025 | Glassia |
| Abbvie INC. | $146.69 | 2021-2024 | |
| Medtronic, INC. | $143.64 | 2022 | |
| Glaxosmithkline, LLC. | $131.45 | 2023-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Ani Pharmaceuticals, INC. | $125.41 | 2024-2025 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $121.32 | 2022 | |
| Amgen INC. | $100.22 | 2024-2025 | Tezspire |
| Pfizer INC. | $64.77 | 2024 | |
| United Therapeutics Corporation | $64.06 | 2025 | Tyvaso |
| Baxter Healthcare | $45.19 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Pulmonx Corporation | $43.67 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Janssen Pharmaceuticals, INC | $37.32 | 2024 | Xarelto |
| Philips North America LLC | $36.80 | 2024 | (Ak6) Vest Therapy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $33.59 | 2025 | Opsumit |
| Grifols USA, LLC | $33.12 | 2025 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $30.82 | 2025 | Winrevair |
| Insmed, INC. | $24.19 | 2024 | Arikayce |
| Novartis Pharmaceuticals Corporation | $14.40 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Bhogaita listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.